Breast Cancer Awareness Month 2023 – #wearitpink

Awareness of breast cancer has increased exponentially over the last few years, with #WearItPink day now being one of the largest fundraising events in the UK. On 20 October each year, thousands of people choose to wear pink to support the Breast Cancer Now, the UK’s largest breast cancer charity.

It’s been over 20 years since people started wearing it pink in October, and have raised over £39 million pounds to support the charity. Breast Cancer Now has made incredible breakthroughs and supported people with breast cancer through some of their most difficult days.

But it doesn’t stop there. The charity wants to make sure that everyone who gets a breast cancer diagnosis survives, and can live a long and fulfilling life. In honour of this amazing charity, we’ve gathered a selection of articles about vital research that aims to understand exactly what causes this disease, and how we can best beat it.

Wei Yue explores the relationship between hypertension, breast cancer, and the enzyme GRK4 as the enzyme is linked to breast cancer cell proliferation in women. This means it could be a good therapeutic target for breast cancer.

A link between GRK4, hypertension, and breast cancer

The enzyme GRK4 (G protein-coupled receptor kinase 4) is implicated in the development of both hypertension (high blood pressure) and breast cancer. Dr Wei Yue and colleagues at the University of Virginia, USA, investigate the relationship between GRK4 and these two diseases. Identification of hypertension-associated GRK4 genetic variations in breast cancer cells suggests an intrinsic link. Through careful experimental design, Yue’s latest study reveals a role for GRK4 as an independent promoter of breast cancer cell growth and spread. Her research highlights GRK4 as a potential therapeutic target for breast cancer, particularly for individuals with hypertension.

Integrative oncology: Improving survival odds in breast cancer

Cancer can affect a person’s body, mind, and spirit, and there is growing evidence of the beneficial effects of complementary and lifestyle therapies in combination with conventional treatments – known as integrative oncology – to treat the whole person. A thought-provoking study by Terri Crudup and colleagues at IQVIA, in collaboration with the Samueli Foundation, USA, demonstrates the value of integrative oncology in improving both the quality of life and the five-year survival of those with breast cancer. Importantly, it sheds light on patients’ awareness of and access to integrative therapies as well as their therapy needs, perceptions, and beliefs.

The California Breast Cancer Research Program research features

A global challenge: On the lookout for research ideas for the prevention of breast cancer

Two million people are diagnosed with breast cancer each year, and yet research has remained heavily focused on treatment rather than prevention. In California, however, a team of researchers aim to change that. The California Breast Cancer Research Program is launching the Global Challenge to Prevent Breast Cancer – bringing cutting-edge research and ideas pertaining to the prevention of this life-threatening disease to the fore.

A fixed-dose combination treatment for late-stage breast cancer

Current treatment of metastatic breast cancer (MBC) aims to ameliorate symptoms and improve quality of life for patients. Intas Pharmaceuticals Ltd is forging the way ahead for MBC treatment with the world’s first fixed-dose combination (FDC) of two known chemotherapy drugs: ‘capecitabine’ and ‘cyclophosphamide’. This unique FDC formulation is based on patented tablet-in-tablet technology, which has been approved by the regulatory authorities in India based on THE ENCLOSE clinical trial. The combined oral fixed-dose tablet provides the advantage of ease of dosing, better patient adherence, and a manageable tablet load for patients with breast cancer.


Related posts.


Leave a Comment

Your email address will not be published. Required fields are marked *

Share this article.